Guardion Health Sciences, Inc. (GHSI): Price and Financial Metrics

Guardion Health Sciences, Inc. (GHSI)

Today's Latest Price: $0.18 USD

0.01 (-4.53%)

Updated Oct 30 12:58pm

Add GHSI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 34 in Consumer Goods

See all "A" rated Strong Buy stocks

GHSI Stock Summary

  • With a market capitalization of $16,782,189, Guardion Health Sciences Inc has a greater market value than just 6.09% of US stocks.
  • Guardion Health Sciences Inc's stock had its IPO on April 5, 2019, making it an older stock than merely 2.4% of US equities in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for GHSI comes in at -100.86% -- higher than that of just 4.43% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Guardion Health Sciences Inc, a group of peers worth examining would be CWCO, WDR, HIHO, MMI, and CSWI.
  • GHSI's SEC filings can be seen here. And to visit Guardion Health Sciences Inc's official web site, go to

GHSI Stock Price Chart Interactive Chart >

Price chart for GHSI

GHSI Price/Volume Stats

Current price $0.18 52-week high $0.74
Prev. close $0.19 52-week low $0.17
Day low $0.18 Volume 1,108,196
Day high $0.19 Avg. volume 7,327,776
50-day MA $0.23 Dividend yield N/A
200-day MA $0.37 Market Cap 16.00M

Guardion Health Sciences, Inc. (GHSI) Company Bio

Guardion Health Sciences, Inc. provides health care services. It offers, Lumega-Z a medical food formulated to replenish and restore the macular protective pigment. The firm also develops medical devices that measures macular pigment density. The company was founded by Michael Favish in 2009 and is headquartered in San Diego, CA.

GHSI Latest News Stream

Event/Time News Detail
Loading, please wait...

GHSI Latest Social Stream

Loading social stream, please wait...

View Full GHSI Social Stream

Latest GHSI News From Around the Web

Below are the latest news stories about Guardion Health Sciences Inc that investors may wish to consider to help them evaluate GHSI as an investment opportunity.

Guardion Health Sciences, Inc.'s (GHSI) CEO Dr. David Evans on Q2 2020 Results - Earnings Call Transcript

Guardion Health Sciences, Inc. (GHSI) Q2 2020 Results Earnings Conference Call August 12, 2020, 4:30 PM ET Company Participants Todd Kehrli - MKR Investor Relations Dr. David Evans - Interim Chief Executive Officer and CSO Andy Schmidt - Chief Financial Officer Conference Call Participants Presentation Operator Good day. And welcome...

SA Transcripts on Seeking Alpha | August 12, 2020

Guardion Health Sciences Adds Experienced Vice President and Chief Financial Officer to Executive Management Team

Newly-Appointed CFO Andrew Schmidt BringsExtensive and Wide-Ranging Public Company Experience San Diego, California, July 21, 2020 -- Guardion Health Sciences, Inc..

Yahoo | July 21, 2020

VectorVision receives Korean approval for CSV-2000 trademark

VectorVision, a wholly-owned subsidiary of Guardion Health Sciences ([[GHSI]] +0.4%) has received approval from the Korean Intellectual Property Office for the VectorVision CSV-2000, the first and only device that provides standardized contrast sensitivity testing along with the full range of visual acuity, color, astigmatism, fixation and other standard vision tests....

Seeking Alpha | July 15, 2020

Guardion Subsidiary VectorVision Receives Approval from Korean Intellectual Property Office for CSV-2000 Trademark

The Only Computer Vision Testing Device to Combine Standardized Contrast Sensitivity Testing with a Full Suite of Clinical Vision Tests San Diego, California, July 15, 2020 --.

Yahoo | July 15, 2020

Guardion Health Sciences Announces Submission of Patent Application for Treatment of Certain Underlying Conditions Related to Eye Disease

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), a specialty health sciences company that develops medical foods and medical devices in the ocular health marketplace and which is developing nutraceuticals it believes will provide medicinal and health benefits to consumers, announced that it has submitted a formal patent application to the U.S. Patent and Trademark Office seeking to protect its proprietary formula, currently marketed by Guardion as GlaucoCetin. GlaucoCetin provides nutritional support to help manage certain underlying conditions related to eye disease.

Yahoo | July 8, 2020

Read More 'GHSI' Stories Here

GHSI Price Returns

1-mo -10.18%
3-mo -57.43%
6-mo -62.10%
1-year -33.55%
3-year N/A
5-year N/A
YTD -18.29%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.704 seconds.